Analysts Expect Amyris Inc (AMRS) Will Post Quarterly Sales of $32.21 Million

Share on StockTwits

Wall Street analysts expect Amyris Inc (NASDAQ:AMRS) to report $32.21 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Amyris’ earnings. The lowest sales estimate is $30.02 million and the highest is $34.40 million. Amyris reported sales of $23.00 million during the same quarter last year, which indicates a positive year-over-year growth rate of 40%. The firm is expected to report its next quarterly earnings results on Monday, May 13th.

On average, analysts expect that Amyris will report full-year sales of $237.56 million for the current fiscal year, with estimates ranging from $225.22 million to $249.90 million. For the next fiscal year, analysts forecast that the company will report sales of $329.75 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Amyris.

Amyris (NASDAQ:AMRS) last issued its quarterly earnings data on Monday, March 18th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.44 by ($1.51). The company had revenue of $19.36 million during the quarter, compared to the consensus estimate of $98.52 million. During the same quarter in the previous year, the business earned $0.61 EPS. The business’s quarterly revenue was down 76.0% compared to the same quarter last year.

A number of equities research analysts recently issued reports on the company. HC Wainwright set a $11.00 price objective on Amyris and gave the stock a “buy” rating in a research report on Tuesday, February 5th. BidaskClub downgraded Amyris from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Finally, Zacks Investment Research upgraded Amyris from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Amyris presently has a consensus rating of “Buy” and an average target price of $8.83.

Several hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its position in shares of Amyris by 8.6% in the third quarter. Bank of New York Mellon Corp now owns 115,388 shares of the biotechnology company’s stock worth $916,000 after buying an additional 9,172 shares in the last quarter. Balasa Dinverno & Foltz LLC raised its position in Amyris by 99.6% during the fourth quarter. Balasa Dinverno & Foltz LLC now owns 23,711 shares of the biotechnology company’s stock valued at $79,000 after purchasing an additional 11,834 shares in the last quarter. GSA Capital Partners LLP raised its position in Amyris by 18.9% during the fourth quarter. GSA Capital Partners LLP now owns 76,665 shares of the biotechnology company’s stock valued at $256,000 after purchasing an additional 12,200 shares in the last quarter. Wells Fargo & Company MN raised its position in Amyris by 50.6% during the third quarter. Wells Fargo & Company MN now owns 41,903 shares of the biotechnology company’s stock valued at $333,000 after purchasing an additional 14,075 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Amyris during the fourth quarter valued at about $48,000. Institutional investors own 36.69% of the company’s stock.

Shares of AMRS stock traded up $0.58 on Friday, reaching $3.45. The company’s stock had a trading volume of 6,741,479 shares, compared to its average volume of 3,647,372. Amyris has a 12-month low of $1.87 and a 12-month high of $9.28. The company has a market capitalization of $219.64 million, a PE ratio of -1.36 and a beta of 0.29.

Amyris Company Profile

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Recommended Story: Why is Cost of Capital Important?

Get a free copy of the Zacks research report on Amyris (AMRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Set Bunzl plc  Target Price at $2,481.25
Brokerages Set Bunzl plc Target Price at $2,481.25
Analysts Expect Amyris Inc  Will Post Quarterly Sales of $32.21 Million
Analysts Expect Amyris Inc Will Post Quarterly Sales of $32.21 Million
Filta Group Holdings PLC  Declares Dividend of GBX 0.92
Filta Group Holdings PLC Declares Dividend of GBX 0.92
Ironwood Pharmaceuticals, Inc.  Receives Consensus Recommendation of “Hold” from Analysts
Ironwood Pharmaceuticals, Inc. Receives Consensus Recommendation of “Hold” from Analysts
OsmiumCoin  Price Hits $0.0265 on Top Exchanges
OsmiumCoin Price Hits $0.0265 on Top Exchanges
Beazley PLC  Receives GBX 628 Consensus PT from Brokerages
Beazley PLC Receives GBX 628 Consensus PT from Brokerages


© 2006-2019 Ticker Report